Q4 2024 Management View CEO Jacob Thaysen highlighted the transformative progress Illumina made in 2024, emphasizing its strategic roadmap targeting high single-digit revenue growth by 2027. He noted ...

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through ...

Illumina shares tumbled 8% Friday on investor concerns about the future of the gene-sequencing equipment maker’s business in China, growing competitive threats, and the potential for Trump ...

Shares of Illumina (NASDAQ: ILMN) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. ET. At that time ...

Illumina is an applied genomics technology company that was founded in 1998 with the mission statement: ‘To improve human health by unlocking the power of the genome’. Over the past two ...

Illumina Inc (NASDAQ:ILMN). reported stronger-than-expected earnings for the fourth quarter of 2024, with both earnings per share (EPS) and revenue surpassing analysts' forecasts. Despite the positive ...